May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Methotrexate Therapy For Clasic Pars Planitis
Author Affiliations & Notes
  • C.P. Jaime–Fonseca, III
    Ophthalmology, Hospital, Mexico, Mexico
  • E. López–Star
    Ophthalmology, Hospital, Mexico, Mexico
  • F. Martínez–Castro
    Ophthalmology, Hospital, Mexico, Mexico
  • T. Váldez–González
    Ophthalmology, Hospital, Mexico, Mexico
  • Footnotes
    Commercial Relationships  C.P. Jaime–Fonseca, None; E. López–Star, None; F. Martínez–Castro, None; T. Váldez–González, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2432. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.P. Jaime–Fonseca, III, E. López–Star, F. Martínez–Castro, T. Váldez–González; Methotrexate Therapy For Clasic Pars Planitis . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2432.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate usefullness and security of methotrexate in pars planitis patients resistent to conventional therapy. Design: Prospective, comparative, longitudinal and experimental.

Material and Methods: : We included pars planitis patients resistent to conventional antinflamatory therapy from april 2004 to octuber 2005. They recived methotrexate 5 mg weekly. Vitreous cells were assessed at each visit as well as best corrected visual acuity and liver function before an after the treatment.

Results: : Twenty three patients (46 eyes) were included. Fourteen men (61%), from 5 to 25 years old (11±5 years). 15 patients had pars planitis and or steroids complications before treatment with methotrexate: lens opacity 27 eyes, posterior sinequiae 11 eyes, band keratopathy 16 eyes, vitreous hemorrhage, macular edema, macular hole in 5 eyes. At the end of follow up 43 eyes (94%) improved vitreous cells. In fourteen patients (61%) inflammatory activity was eliminated. Liver function was affected in 7 patients but only one requires to stop treatment.

Conclusions: : Methotrexate is and ussefull option of patients with pars planitis unresponsive to conventional therapy, with few adverse effects. Keys words: pars planitis, methotrexate, vitreous cells.

Keywords: uveitis-clinical/animal model • uvea • inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.